AstraZeneca Posts Solid Q3 Numbers as NatWest Q3 Profits Slip
AstraZeneca reported a 7% increase in total revenue for the nine months ended September 30 and said core earnings per share rose 14%. The report also says NatWest Q3 profits slipped, without providing a figure.